# A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)

Study · id `cardio:ct-nct07821944` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07821944](<https://clinicaltrials.gov/study/NCT07821944>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07821944

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07821944. Randomized; triple masking; primary purpose treatment. Start 2026-10-15 (actual); primary completion 2027-11-26 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07821944, source copy `cardio:ctgov-nct07821944-2026-11-02`, retrieved 2026-11-18)
- Started: 2026-10-15 (actual) (ClinicalTrials.gov record NCT07821944, source copy `cardio:ctgov-nct07821944-2026-11-02`, retrieved 2026-11-18)
- Primary completion: 2027-11-26 (anticipated) (ClinicalTrials.gov record NCT07821944, source copy `cardio:ctgov-nct07821944-2026-11-02`, retrieved 2026-11-18)
- Completion: 2027-11-26 (anticipated) (ClinicalTrials.gov record NCT07821944, source copy `cardio:ctgov-nct07821944-2026-11-02`, retrieved 2026-11-18)
- Countries: India (ClinicalTrials.gov record NCT07821944, source copy `cardio:ctgov-nct07821944-2026-11-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07821944-2026-11-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
- Condition: Hyperlipidemia
- Condition: Hypercholesterolemia
- Intervention (Drug): Enlicitide Decanoate
- Intervention (Other): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 1028bb05b76f2ebf9833e47e04ffeb5f795d6e8e508720a1382adf20f1d7e22b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
